Effects of cannabidiol rich cannabis extract on disease severity and quality of life in parkinson disease
Phase 1
Completed
- Conditions
- Parkinson diseaseCannabidiolcannabis extract
- Registration Number
- TCTR20210303005
- Lead Sponsor
- /A
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Completed
- Sex
- All
- Target Recruitment
- 40
Inclusion Criteria
1.Clinical diagnosis of Parkinson disease, with a disease severity rating of stage 1 to 4 on the Hoehn and Yahr scale
2.stable medication use
Exclusion Criteria
1.Dementia
2.History of ischemic heart disease or arrythmia
3.History of tobacco or alcoholic use
4.History of psychotic illness
5.History of opioid drug use
6.History of using drug that have drug interaction with cannabis extract
7.History of cannabis use
8.Pregnancy and lactation
9.Abnormal liver function test
10.Abnormal renal function test
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Disease severity 8 weeks Unified Parkinson Disease Rating score
- Secondary Outcome Measures
Name Time Method Gait and balance 8 weeks Time up and Go test,Gait velocity 8 weeks 10 metres walk test,Balance 8 weeks 5 times sit to stand,Quality of life 8 weeks Health-related quality of life developed by the Euro Quality of life group score,Anxiety and Depression 8 weeks Thai Hospital Anxiety and depression score,Side effect 8 weeks Side effect,laboratory marker 8 weeks laboratory marker